The seafood salad may be of particular risk to those customers who have an allergy or severe sensitivity to soy, the FDA has ...

尽管不受委员会建议的约束，但 FDA 在做出批准决定时会考虑这些建议。预计将于 2024 年 12 月 20 日做出监管决定。如果获得批准，索他格列净将成为首个用于治疗 1 型糖尿病患者的口服药物。

Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic ...

The U.S. Food and Drug Administration is weighing the need for a regulatory action on bluebird bio's gene therapy for a rare ...

The co-leader of President-elect Donald Trump’s initiative to cut government spending has a financial stake in the biotech ...

A judge has dismissed a lawsuit against the U.S. Food and Drug Administration by a lawyer who objected to being identified in ...

The FDA said on Wednesday that it is investigating reports of blood cancers -- including life-threatening cases of ...

President-elect Donald Trump’s Friday night news dump of health care nominees included the expected naming of Dr. Marty ...

11月19日，美国食药监局（FDA）官网发布了对 达仁堂 （600329.SH）全资子公司、中华老字号企业京万红的警告信。

智通财经APP获悉，亨特布鲁克传媒公司(Hunterbrook Media)表示，Hims & Hers Health(HIMS.US)将成为当选总统唐纳德·特朗普提名马蒂·马卡里(Marty ...

PTC Therapeutics决定以1.5亿美元出售其罕见儿科疾病优先审查凭证，与公司的财务状况和市场表现相一致。根据InvestingPro数据，PTC Therapeutics的市值为35.5亿美元，反映了其在生物制药行业的重要地位。

碳酸司维拉姆还是目前唯一被美国食品药品监督管理局（FDA）批准的既不含钙、又不含其他金属的新一代磷结合剂，被国内外指南和规范一致推荐为降磷首选药物。该产品以离子交换方式吸附肠胃道中的磷酸，其结合物由粪便排出体外，无全身性吸收，安全性高。